Eris Lifesciences Limited

BSE: 540596 NSE: ERIS
Eris Lifesciences Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials and compliance.
CIN L24232GJ2007PLC049867 Incorporated 25 January 2007 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: ERIS · BSE: 540596 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹3,129.42 Cr
▲ 8.15% YoY
Computed EBITDA · FY 2026
₹1,127.86 Cr
▲ 8.91% YoY
Net profit · FY 2026
₹647.51 Cr
▲ 72.82% YoY
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹13.86 Cr
Issued & subscribed
Open charges
₹1,524.82 Cr
Satisfied ₹1,252.5 Cr
Company age
19 yrs
Est. 2007
Employees · EPFO
3,131
Latest available

About Eris Lifesciences Limited

Data last updated: 14 July 2026

Eris Lifesciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 25 January 2007, the company has been in operation for over 19 years.

Registered with ROC Ahmedabad under CIN L24232GJ2007PLC049867. Listed on BSE: 540596 and NSE: ERIS.

Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹13.86 Cr. Formerly known as Eris Lifesciences Private Limited and Eris Lifescience Private Limited. It is led by directors including Kalpana Vasantrai Unadkat and Vasudevan Sujesh.

Last AGM: 25 July 2025. Financial statements filed for year ended 31 March 2025. Office: Shivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹3,129.42 Cr, a growth of 8.15% compared to the previous year. The net worth stands at ₹3,895.66 Cr (up 19.07% YoY). Total assets are valued at ₹7,365.51 Cr (up 4.73% YoY).

The company has a workforce of approximately 3,131 employees as per the latest available data. Its group structure includes 6 subsidiaries.

The company is associated with 1 brand - Eris Life Sciences. As per MCA filings, the company has open charges of ₹1,524.82 Cr and satisfied charges of ₹1,252.5 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eris.co.in.

Company Details of Eris Lifesciences Limited
CIN L24232GJ2007PLC049867
Registration Number 049867
Incorporation Date 25 January 2007
ROC Ahmedabad
Listing Status Listed (BSE: 540596, NSE: ERIS)
Company Status Active
Date of Last AGM 25 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Amit Indubhushan Bakshi Managing Director Inderjeet Singh Negi Whole-Time Director Kaushal Kamlesh Shah Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    eris.co.in
  • Social Media
    Locked
  • Registered Address
    Shivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054
  • Industry
    Pharma, Drug Formulation & Development
Company report
Eris Lifesciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Eris Lifesciences Limited report

Financials, compliance, directors, charges, ownership and filings for Eris Lifesciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Eris Lifesciences Limited

Eris Lifesciences Limited has undergone 2 name changes throughout its history. The company was previously known as Eris Lifesciences Private Limited, and Eris Lifescience Private Limited. The current legal name is Eris Lifesciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Eris Lifesciences Limited Current
Eris Lifesciences Private Limited Previous
Eris Lifescience Private Limited Previous

CIN History of Eris Lifesciences Limited

Eris Lifesciences Limited has one previous CIN (Corporate Identification Number): U24232GJ2007PLC049867. The current CIN is L24232GJ2007PLC049867, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24232GJ2007PLC049867 Current
U24232GJ2007PLC049867 Previous

Associated Brands with Eris Lifesciences Limited

Eris Lifesciences Limited operates one associated brand: ERIs Life Sciences. These brands represent Eris Lifesciences Limited's diversified market presence and brand portfolio.

Brand Description Website
ERIs Life Sciences
Pharmaceutical formulations for chronic diseases are manufactured and studied. eris.co.in

Business Activity of Eris Lifesciences Limited

Eris Lifesciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Eris Lifesciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Eris Lifesciences Limited

Eris Lifesciences Limited is audited by Walker Chandiok &Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Walker Chandiok &Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Eris Lifesciences Limited

Eris Lifesciences Limited is currently managed by 8 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Kalpana Vasantrai Unadkat
Also directs: Tvs Motor Company Limited, Avenue Supermarts Limited, Tvs Credit Services Limited
Director 05 Jan 2021 5 Years 8 Months Current
Vasudevan Sujesh
Also directs: Eris Therapeutics Limited, Entero Healthcare Solutions Limited, Hetero Labs Limited
Director 25 Jul 2022 4 Years 1 Months Current
Amit Indubhushan Bakshi
Also directs: Eris M. J. Biopharm Private Limited, Eris Oaknet Healthcare Private Limited, Amit Bakshi Foundation
Managing Director 27 Jan 2007 19 Years 7 Months Current
Inderjeet Singh Negi
Also directs: Eris Healthcare Private Limited, Eris Therapeutics Limited, Eris Bionxt Private Limited and 3 more
Whole-Time Director 25 Jan 2007 19 Years 7 Months Current
Prashant Gupta Director 30 Apr 2018 8 Years 4 Months Current
Kaushal Kamlesh Shah
Also directs: Eris Healthcare Private Limited, Eris Therapeutics Limited, Aprica Healthcare Limited and 5 more
Whole-Time Director 04 Aug 2020 6 Years 1 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Eris Lifesciences Limited FY 2026 filings available

Eris Lifesciences Limited reported revenue of ₹3,129.42 Cr (up 8.15% YoY) for FY 2026.

Revenue · FY 2026
₹3,129.42 Cr ▲ 8.15%
Profit · FY 2026
₹647.51 Cr ▲ 72.82%
Computed EBITDA · FY 2026
₹1,127.86 Cr ▲ 8.91%
Revenue₹ Cr · Consolidated02,0004,000FY 2020: ₹1,074 Cr1,074FY 2020FY 2021: ₹1,212 Cr · +12.8% YoY1,212+12.8%FY 2021FY 2022: ₹1,347 Cr · +11.2% YoY1,347+11.2%FY 2022FY 2023: ₹1,685 Cr · +25.1% YoY1,685+25.1%FY 2023FY 2024: ₹2,009 Cr · +19.2% YoY2,009+19.2%FY 2024FY 2025: ₹2,894 Cr · +44% YoY2,894+44%FY 2025FY 2026: ₹3,129 Cr · +8.1% YoY3,129+8.1%FY 2026
Net Profit₹ Cr · Consolidated0250500750FY 2020: ₹297 Cr297FY 2020FY 2021: ₹355 Cr · +19.8% YoY355+19.8%FY 2021FY 2022: ₹406 Cr · +14.3% YoY406+14.3%FY 2022FY 2023: ₹374 Cr · -7.8% YoY374-7.8%FY 2023FY 2024: ₹397 Cr · +6.1% YoY397+6.1%FY 2024FY 2025: ₹375 Cr · -5.6% YoY375-5.6%FY 2025FY 2026: ₹648 Cr · +72.8% YoY648+72.8%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,000Q1'25: ₹720 Cr · +54.2% YoY720+54.2%Q1'25Q2'25: ₹739 Cr · +46.2% YoY739+46.2%Q2'25Q3'25: ₹727 Cr · +49.6% YoY727+49.6%Q3'25Q4'25: ₹705 Cr · +28% YoY705+28%Q4'25Q1'26: ₹773 Cr · +7.4% YoY773+7.4%Q1'26Q2'26: ₹792 Cr · +7.2% YoY792+7.2%Q2'26Q3'26: ₹807 Cr · +11% YoY807+11%Q3'26Q4'26: ₹757 Cr · +7.3% YoY757+7.3%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,129.42 Cr ₹2,893.64 Cr ₹2,009.14 Cr ₹1,685.15 Cr ₹1,347.04 Cr ₹1,211.86 Cr ₹1,074.06 Cr
Other Income ₹7.75 Cr ₹18.36 Cr ₹23.82 Cr ₹11.15 Cr ₹26.09 Cr ₹8.71 Cr ₹15.4 Cr
Total Income ₹3,137.17 Cr ₹2,912 Cr ₹2,032.96 Cr ₹1,696.3 Cr ₹1,373.14 Cr ₹1,220.57 Cr ₹1,089.46 Cr
Cost of Materials Consumed ₹326.65 Cr ₹276.34 Cr ₹177.81 Cr ₹142.2 Cr ₹117.57 Cr ₹99.43 Cr ₹76.88 Cr
Purchases of Stock-in-Trade ₹490.56 Cr ₹473.12 Cr ₹201.52 Cr ₹206.33 Cr ₹141.72 Cr ₹177.01 Cr ₹73.24 Cr
Changes in Inventories -₹21.61 Cr -₹35.47 Cr ₹72.1 Lakh ₹3.82 Cr -₹77.6 Lakh -₹38.17 Cr ₹21.41 Cr
Employee Benefit Expense ₹556.81 Cr ₹505.09 Cr ₹403.82 Cr ₹346.16 Cr ₹252.25 Cr ₹229.3 Cr ₹205.69 Cr
Finance Costs ₹192.67 Cr ₹231.29 Cr ₹84.8 Cr ₹26.17 Cr ₹4.15 Cr ₹1.8 Cr ₹2.16 Cr
Depreciation & Amortisation ₹279.5 Cr ₹315.46 Cr ₹182.61 Cr ₹117.09 Cr ₹64.71 Cr ₹42.99 Cr ₹50.26 Cr
Other Expenses ₹656.9 Cr ₹657.36 Cr ₹550.45 Cr ₹449.9 Cr ₹351.32 Cr ₹313.72 Cr ₹328.46 Cr
Total Expenses ₹2,481.48 Cr ₹2,423.19 Cr ₹1,601.72 Cr ₹1,291.66 Cr ₹930.94 Cr ₹826.07 Cr ₹758.11 Cr
Profit Before Exceptional Items & Tax ₹655.69 Cr ₹488.81 Cr ₹431.24 Cr ₹404.64 Cr ₹442.2 Cr ₹394.5 Cr ₹331.35 Cr
Exceptional Items -₹17.24 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹638.45 Cr ₹488.81 Cr ₹431.24 Cr ₹404.64 Cr ₹442.2 Cr ₹394.5 Cr ₹331.35 Cr
Total Tax Expense -₹8.97 Cr ₹114.2 Cr ₹34.19 Cr ₹30.48 Cr ₹36.41 Cr ₹39.36 Cr ₹34.84 Cr
Net Profit ₹647.51 Cr ₹374.67 Cr ₹397.05 Cr ₹374.16 Cr ₹405.79 Cr ₹355.14 Cr ₹296.51 Cr
  attributable to Owners ₹619.52 Cr ₹351.84 Cr ₹391.98 Cr ₹382.16 Cr ₹406.11 Cr ₹355.14 Cr -
  attributable to NCI ₹27.99 Cr ₹22.83 Cr ₹5.07 Cr -₹8 Cr -₹32.4 Lakh ₹0 -
Other Comprehensive Income -₹1.44 Cr -₹3.29 Cr -₹3.05 Cr ₹5.9 Lakh -₹98.2 Lakh -₹1.49 Cr -₹1.22 Cr
Total Comprehensive Income ₹646.07 Cr ₹371.38 Cr ₹394 Cr ₹374.22 Cr ₹404.81 Cr ₹353.65 Cr ₹295.29 Cr
EBITDA (computed) ₹1,127.86 Cr ₹1,035.56 Cr ₹698.65 Cr ₹547.9 Cr ₹511.05 Cr ₹439.28 Cr ₹383.77 Cr
Basic EPS ₹45.33 ₹25.85 ₹28.82 ₹28.10 ₹29.89 ₹26.16 ₹21.61
Diluted EPS ₹45.26 ₹25.81 ₹28.79 ₹28.07 ₹29.88 ₹26.14 ₹21.59
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹7,365.51 Cr ₹7,033.17 Cr ₹7,048.84 Cr ₹3,667.33 Cr
Non-current Assets ₹5,825.66 Cr ₹5,770.64 Cr ₹4,746.76 Cr ₹2,902.61 Cr
Current Assets ₹1,539.85 Cr ₹1,262.53 Cr ₹2,302.07 Cr ₹764.72 Cr
Property, Plant & Equipment ₹708.37 Cr ₹662.07 Cr ₹504.6 Cr ₹356 Cr
Inventories ₹436.82 Cr ₹334.83 Cr ₹189.03 Cr ₹131.44 Cr
Trade Receivables ₹680.34 Cr ₹458.64 Cr ₹422.02 Cr ₹292.71 Cr
Cash & Equivalents ₹54.74 Cr ₹199.74 Cr ₹94.25 Cr ₹56.02 Cr
Equity (Net Worth) ₹3,895.66 Cr ₹3,271.76 Cr ₹3,222.03 Cr ₹2,220.68 Cr
Equity Share Capital ₹13.85 Cr ₹13.62 Cr ₹13.6 Cr ₹13.6 Cr
Borrowings (Non-current) ₹955.83 Cr ₹1,781.72 Cr ₹654.51 Cr ₹644.45 Cr
Borrowings (Current) ₹1,353.85 Cr ₹696.2 Cr ₹2,080.76 Cr ₹185.57 Cr
Total Debt (computed) ₹2,309.68 Cr ₹2,477.92 Cr ₹2,735.27 Cr ₹830.02 Cr
Current Liabilities ₹2,077.1 Cr ₹1,381.39 Cr ₹2,532.08 Cr ₹443.23 Cr
Total Liabilities ₹3,469.85 Cr ₹3,761.41 Cr ₹3,826.81 Cr ₹1,446.65 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹537.99 Cr ₹1,065.01 Cr ₹486.01 Cr ₹291.74 Cr ₹378.26 Cr
Investing Cash Flow -₹369.46 Cr -₹79.97 Cr -₹1,827.56 Cr -₹974.61 Cr -₹319.61 Cr
Financing Cash Flow -₹313.53 Cr -₹881.32 Cr ₹1,379.78 Cr ₹688.03 Cr -₹44.7 Cr
Capital Expenditure ₹296.86 Cr ₹155 Cr ₹129.16 Cr ₹841.42 Cr ₹121.03 Cr
Free Cash Flow (computed) ₹241.13 Cr ₹910.01 Cr ₹356.84 Cr -₹549.68 Cr ₹257.23 Cr
Dividends Paid ₹0 ₹100.05 Cr ₹0 ₹99.91 Cr ₹81.62 Cr
Net Change in Cash -₹145 Cr ₹103.72 Cr ₹38.22 Cr ₹5.15 Cr ₹13.96 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹756.56 Cr ₹807.45 Cr ₹792.41 Cr ₹773 Cr ₹705.3 Cr ₹727.45 Cr ₹738.95 Cr ₹719.72 Cr ₹550.93 Cr ₹486.3 Cr ₹505.3 Cr ₹466.62 Cr
Other Income ₹2.23 Cr ₹2 Lakh ₹2.81 Cr ₹2.69 Cr ₹7.95 Cr ₹4.22 Cr ₹6.77 Cr ₹1.64 Cr ₹15.15 Cr ₹4.2 Cr ₹3.48 Cr ₹98.9 Lakh
Total Income ₹758.79 Cr ₹807.47 Cr ₹795.22 Cr ₹775.69 Cr ₹713.25 Cr ₹731.67 Cr ₹745.72 Cr ₹721.36 Cr ₹566.07 Cr ₹490.49 Cr ₹508.78 Cr ₹467.61 Cr
Cost of Materials Consumed ₹68.12 Cr ₹105.85 Cr ₹82.58 Cr ₹70.1 Cr ₹68.28 Cr ₹69.43 Cr ₹72.16 Cr ₹66.47 Cr ₹51.17 Cr ₹38.91 Cr ₹48.17 Cr ₹39.56 Cr
Purchases of Stock-in-Trade ₹122.97 Cr ₹117.24 Cr ₹146.09 Cr ₹104.26 Cr ₹95.98 Cr ₹133.22 Cr ₹118.35 Cr ₹125.57 Cr ₹58.51 Cr ₹50.03 Cr ₹53.77 Cr ₹39.2 Cr
Changes in Inventories -₹5.84 Cr ₹21 Lakh -₹26.26 Cr ₹10.28 Cr ₹5.99 Cr -₹25.77 Cr -₹4.24 Cr -₹11.45 Cr ₹8.5 Cr -₹6.9 Lakh -₹7.34 Cr -₹36.6 Lakh
Employee Benefit Expense ₹136.85 Cr ₹138.08 Cr ₹137.45 Cr ₹144.43 Cr ₹121.45 Cr ₹125.39 Cr ₹125.63 Cr ₹132.62 Cr ₹102.48 Cr ₹98.68 Cr ₹98.53 Cr ₹104.13 Cr
Finance Costs ₹45.62 Cr ₹48.82 Cr ₹49.55 Cr ₹48.68 Cr ₹54.28 Cr ₹57.17 Cr ₹59.47 Cr ₹60.37 Cr ₹33.03 Cr ₹18.12 Cr ₹16.3 Cr ₹17.36 Cr
Depreciation & Amortisation ₹69.57 Cr ₹70.34 Cr ₹69.08 Cr ₹70.51 Cr ₹77.25 Cr ₹81.2 Cr ₹80.48 Cr ₹75.94 Cr ₹53.9 Cr ₹45.72 Cr ₹42.09 Cr ₹40.89 Cr
Other Expenses ₹160.89 Cr ₹164.46 Cr ₹164.34 Cr ₹167.22 Cr ₹161.21 Cr ₹174.87 Cr ₹164.76 Cr ₹156.52 Cr ₹181.84 Cr ₹123.24 Cr ₹131.03 Cr ₹114.35 Cr
Total Expenses ₹598.18 Cr ₹645 Cr ₹622.83 Cr ₹615.48 Cr ₹584.44 Cr ₹615.51 Cr ₹616.61 Cr ₹606.04 Cr ₹489.43 Cr ₹374.62 Cr ₹382.54 Cr ₹355.13 Cr
Profit Before Exceptional Items & Tax ₹160.61 Cr ₹162.47 Cr ₹172.39 Cr ₹160.21 Cr ₹128.81 Cr ₹116.16 Cr ₹129.11 Cr ₹115.32 Cr ₹76.65 Cr ₹115.87 Cr ₹126.24 Cr ₹112.48 Cr
Exceptional Items ₹0 -₹17.24 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹160.61 Cr ₹145.23 Cr ₹172.39 Cr ₹160.21 Cr ₹128.81 Cr ₹116.16 Cr ₹129.11 Cr ₹115.32 Cr ₹76.65 Cr ₹115.87 Cr ₹126.24 Cr ₹112.48 Cr
Total Tax Expense -₹119.69 Cr ₹36.52 Cr ₹38.2 Cr ₹36 Cr ₹26.52 Cr ₹29.23 Cr ₹32.76 Cr ₹25.9 Cr -₹2.99 Cr ₹14.41 Cr ₹3.92 Cr ₹18.84 Cr
Net Profit ₹279.1 Cr ₹108.83 Cr ₹134.47 Cr ₹125.1 Cr ₹102.35 Cr ₹86.93 Cr ₹96.35 Cr ₹89.42 Cr ₹79.63 Cr ₹101.46 Cr ₹122.31 Cr ₹93.65 Cr
  attributable to Owners ₹281.61 Cr ₹99.72 Cr ₹120.19 Cr ₹117.99 Cr ₹93.84 Cr ₹83.63 Cr ₹91.59 Cr ₹83.18 Cr ₹70.96 Cr ₹102.74 Cr ₹123.43 Cr ₹94.86 Cr
  attributable to NCI -₹2.51 Cr ₹9.11 Cr ₹14.28 Cr ₹7.11 Cr ₹8.51 Cr ₹3.3 Cr ₹4.77 Cr ₹6.24 Cr ₹8.67 Cr -₹1.28 Cr -₹1.12 Cr -₹1.21 Cr
Other Comprehensive Income ₹44 Lakh -₹74 Lakh -₹57 Lakh -₹57 Lakh -₹1.95 Cr -₹39 Lakh -₹16 Lakh -₹79 Lakh -₹41.2 Lakh -₹32.9 Lakh -₹2.39 Cr ₹7.8 Lakh
Total Comprehensive Income ₹279.54 Cr ₹108.09 Cr ₹133.9 Cr ₹124.53 Cr ₹100.4 Cr ₹86.54 Cr ₹96.19 Cr ₹88.63 Cr ₹79.22 Cr ₹101.13 Cr ₹119.92 Cr ₹93.73 Cr
EBITDA (computed) ₹275.8 Cr ₹281.63 Cr ₹291.02 Cr ₹279.4 Cr ₹260.34 Cr ₹254.53 Cr ₹269.06 Cr ₹251.63 Cr ₹163.58 Cr ₹179.71 Cr ₹184.63 Cr ₹170.73 Cr
Basic EPS ₹20.60 ₹7.32 ₹8.82 ₹8.66 ₹6.90 ₹6.15 ₹6.73 ₹6.11 ₹5.22 ₹7.55 ₹9.08 ₹6.97
Diluted EPS ₹20.57 ₹7.31 ₹8.81 ₹8.64 ₹6.89 ₹6.14 ₹6.72 ₹6.10 ₹5.21 ₹7.54 ₹9.06 ₹6.97
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,821.74 Cr ₹1,697.75 Cr ₹1,486.71 Cr ₹1,330.73 Cr ₹1,215.73 Cr ₹1,108.83 Cr ₹1,020.23 Cr
Other Income ₹98.31 Cr ₹35.51 Cr ₹34.83 Cr ₹17.26 Cr ₹28.99 Cr ₹10 Cr ₹14.73 Cr
Total Income ₹1,920.05 Cr ₹1,733.26 Cr ₹1,521.53 Cr ₹1,347.99 Cr ₹1,244.72 Cr ₹1,118.83 Cr ₹1,034.96 Cr
Cost of Materials Consumed ₹83.99 Cr ₹68.35 Cr ₹96.29 Cr ₹114.13 Cr ₹117.57 Cr ₹99.43 Cr ₹76.88 Cr
Purchases of Stock-in-Trade ₹478.22 Cr ₹474.44 Cr ₹197.02 Cr ₹113.76 Cr ₹79.59 Cr ₹111.65 Cr ₹70 Cr
Changes in Inventories ₹64.49 Cr -₹43.54 Cr -₹13.15 Cr ₹8.5 Cr ₹2.49 Cr -₹12.57 Cr ₹17.47 Cr
Employee Benefit Expense ₹340.62 Cr ₹361.92 Cr ₹331.67 Cr ₹252.52 Cr ₹222.18 Cr ₹207.02 Cr ₹191.73 Cr
Finance Costs ₹179.54 Cr ₹220.24 Cr ₹57.42 Cr ₹20.81 Cr ₹2.99 Cr ₹77.8 Lakh ₹1.85 Cr
Depreciation & Amortisation ₹154.38 Cr ₹181.77 Cr ₹102.39 Cr ₹64.66 Cr ₹51.46 Cr ₹37.64 Cr ₹44.88 Cr
Other Expenses ₹242.09 Cr ₹350.03 Cr ₹421.06 Cr ₹336.71 Cr ₹309.9 Cr ₹285.99 Cr ₹308.54 Cr
Total Expenses ₹1,543.33 Cr ₹1,613.21 Cr ₹1,192.7 Cr ₹911.08 Cr ₹786.18 Cr ₹729.94 Cr ₹711.37 Cr
Profit Before Exceptional Items & Tax ₹376.72 Cr ₹120.05 Cr ₹328.83 Cr ₹436.91 Cr ₹458.54 Cr ₹388.89 Cr ₹323.59 Cr
Exceptional Items -₹14.67 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹362.05 Cr ₹120.05 Cr ₹328.83 Cr ₹436.91 Cr ₹458.54 Cr ₹388.89 Cr ₹323.59 Cr
Total Tax Expense ₹118 Cr ₹42.66 Cr ₹29.12 Cr ₹38.9 Cr ₹41.35 Cr ₹38.29 Cr ₹32.32 Cr
Net Profit ₹244.05 Cr ₹77.39 Cr ₹299.71 Cr ₹398.01 Cr ₹417.19 Cr ₹350.61 Cr ₹291.27 Cr
Other Comprehensive Income ₹69 Lakh -₹2.84 Cr -₹2.76 Cr -₹14.9 Lakh -₹1.01 Cr -₹1.28 Cr -₹1.17 Cr
Total Comprehensive Income ₹244.74 Cr ₹74.55 Cr ₹296.95 Cr ₹397.86 Cr ₹416.19 Cr ₹349.33 Cr ₹290.1 Cr
EBITDA (computed) ₹710.64 Cr ₹522.06 Cr ₹488.64 Cr ₹522.38 Cr ₹512.98 Cr ₹427.31 Cr ₹370.33 Cr
Basic EPS ₹17.86 ₹5.69 ₹22.04 ₹29.27 ₹30.70 ₹25.82 ₹21.23
Diluted EPS ₹17.83 ₹5.68 ₹22.01 ₹29.23 ₹30.70 ₹25.80 ₹21.21
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹5,777.94 Cr ₹5,222.43 Cr ₹5,349.57 Cr ₹2,783.66 Cr
Non-current Assets ₹4,755.13 Cr ₹4,594.89 Cr ₹3,473.02 Cr ₹2,231.58 Cr
Current Assets ₹1,022.81 Cr ₹627.54 Cr ₹1,876.55 Cr ₹552.08 Cr
Property, Plant & Equipment ₹124.19 Cr ₹107.17 Cr ₹148.25 Cr ₹152.4 Cr
Inventories ₹121.36 Cr ₹191.25 Cr ₹91.64 Cr ₹63.7 Cr
Trade Receivables ₹307.16 Cr ₹236.19 Cr ₹239.97 Cr ₹229.22 Cr
Cash & Equivalents ₹25.18 Cr ₹84.34 Cr ₹51.94 Cr ₹47.48 Cr
Equity (Net Worth) ₹3,195.46 Cr ₹2,514.9 Cr ₹2,524.02 Cr ₹2,221.88 Cr
Equity Share Capital ₹13.85 Cr ₹13.62 Cr ₹13.6 Cr ₹13.6 Cr
Borrowings (Non-current) ₹797.62 Cr ₹1,632.64 Cr ₹485.94 Cr ₹209.47 Cr
Borrowings (Current) ₹1,277.94 Cr ₹580.31 Cr ₹2,043.51 Cr ₹107.4 Cr
Total Debt (computed) ₹2,075.56 Cr ₹2,212.95 Cr ₹2,529.45 Cr ₹316.87 Cr
Current Liabilities ₹1,717.73 Cr ₹993.94 Cr ₹2,261.78 Cr ₹283.77 Cr
Total Liabilities ₹2,582.48 Cr ₹2,707.53 Cr ₹2,825.55 Cr ₹561.77 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹563.94 Cr ₹701.87 Cr ₹336.29 Cr ₹322.33 Cr ₹369.41 Cr
Investing Cash Flow -₹694.16 Cr -₹358.99 Cr -₹2,491.89 Cr -₹513.3 Cr -₹267.64 Cr
Financing Cash Flow ₹71.06 Cr -₹310.47 Cr ₹2,160.06 Cr ₹193.75 Cr -₹88.42 Cr
Capital Expenditure ₹49.39 Cr ₹7.62 Cr ₹349.05 Cr ₹311.26 Cr ₹53.28 Cr
Free Cash Flow (computed) ₹514.55 Cr ₹694.25 Cr -₹12.76 Cr ₹11.06 Cr ₹316.13 Cr
Dividends Paid ₹0 ₹100.05 Cr ₹10,000 ₹99.91 Cr ₹81.62 Cr
Net Change in Cash -₹59.16 Cr ₹32.41 Cr ₹4.45 Cr ₹2.78 Cr ₹13.36 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹277.31 Cr ₹315.29 Cr ₹650.5 Cr ₹578.64 Cr ₹404.77 Cr ₹399.73 Cr ₹428.75 Cr ₹456.69 Cr ₹341.3 Cr ₹324.41 Cr ₹409.71 Cr ₹411.29 Cr
Other Income ₹26.97 Cr ₹25.07 Cr ₹23.59 Cr ₹22.68 Cr ₹16.75 Cr ₹7.79 Cr ₹13.62 Cr ₹5.16 Cr ₹20.39 Cr ₹3.43 Cr ₹6.98 Cr ₹4.03 Cr
Total Income ₹304.28 Cr ₹340.36 Cr ₹674.09 Cr ₹601.32 Cr ₹421.52 Cr ₹407.52 Cr ₹442.37 Cr ₹461.85 Cr ₹361.69 Cr ₹327.85 Cr ₹416.68 Cr ₹415.31 Cr
Cost of Materials Consumed ₹22.53 Cr ₹17.05 Cr ₹20.29 Cr ₹24.12 Cr ₹9.83 Cr ₹10.93 Cr ₹23.19 Cr ₹24.4 Cr ₹17.74 Cr ₹23.75 Cr ₹28.64 Cr ₹26.17 Cr
Purchases of Stock-in-Trade ₹122.95 Cr ₹113.75 Cr ₹134.83 Cr ₹106.69 Cr ₹119.02 Cr ₹122.67 Cr ₹112.34 Cr ₹120.41 Cr ₹37.17 Cr ₹36.24 Cr ₹51.43 Cr ₹72.18 Cr
Changes in Inventories -₹7.72 Cr -₹20.77 Cr ₹42.27 Cr ₹50.71 Cr -₹4.53 Cr -₹14.52 Cr -₹10.2 Cr -₹14.29 Cr ₹10.4 Cr ₹4.65 Cr -₹2.95 Cr -₹25.25 Cr
Employee Benefit Expense ₹78.67 Cr ₹82.75 Cr ₹85.42 Cr ₹93.78 Cr ₹81.41 Cr ₹87.04 Cr ₹89.72 Cr ₹103.75 Cr ₹79.52 Cr ₹80.69 Cr ₹81.1 Cr ₹90.36 Cr
Finance Costs ₹42.7 Cr ₹45.2 Cr ₹46.5 Cr ₹45.14 Cr ₹53.16 Cr ₹54.65 Cr ₹56.26 Cr ₹56.17 Cr ₹28.89 Cr ₹15.14 Cr ₹6.55 Cr ₹6.84 Cr
Depreciation & Amortisation ₹38.82 Cr ₹38.66 Cr ₹39.3 Cr ₹37.6 Cr ₹43.38 Cr ₹46.68 Cr ₹46.16 Cr ₹45.55 Cr ₹29.14 Cr ₹28.08 Cr ₹25 Cr ₹20.16 Cr
Other Expenses ₹39.1 Cr ₹45.16 Cr ₹70.81 Cr ₹87.02 Cr ₹78.07 Cr ₹94.04 Cr ₹78.88 Cr ₹99.04 Cr ₹117.08 Cr ₹104.65 Cr ₹107 Cr ₹92.32 Cr
Total Expenses ₹337.05 Cr ₹321.8 Cr ₹439.42 Cr ₹445.06 Cr ₹380.34 Cr ₹401.49 Cr ₹396.35 Cr ₹435.03 Cr ₹319.94 Cr ₹293.2 Cr ₹296.76 Cr ₹282.79 Cr
Profit Before Exceptional Items & Tax -₹32.77 Cr ₹18.56 Cr ₹234.67 Cr ₹156.26 Cr ₹41.18 Cr ₹6.03 Cr ₹46.02 Cr ₹26.82 Cr ₹41.75 Cr ₹34.64 Cr ₹119.92 Cr ₹132.52 Cr
Exceptional Items ₹0 -₹14.67 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹32.77 Cr ₹3.89 Cr ₹234.67 Cr ₹156.26 Cr ₹41.18 Cr ₹6.03 Cr ₹46.02 Cr ₹26.82 Cr ₹41.75 Cr ₹34.64 Cr ₹119.92 Cr ₹132.52 Cr
Total Tax Expense -₹24.17 Cr ₹80 Lakh ₹85.1 Cr ₹56.27 Cr ₹10.71 Cr ₹4.25 Cr ₹17.92 Cr ₹9.78 Cr ₹2.24 Cr ₹2.99 Cr ₹2.11 Cr ₹21.78 Cr
Net Profit -₹8.6 Cr ₹3.09 Cr ₹149.57 Cr ₹99.99 Cr ₹30.47 Cr ₹1.78 Cr ₹28.1 Cr ₹17.04 Cr ₹39.51 Cr ₹31.66 Cr ₹117.81 Cr ₹110.74 Cr
Other Comprehensive Income ₹2.19 Cr -₹50 Lakh -₹50 Lakh -₹50 Lakh -₹1.59 Cr -₹42 Lakh -₹11 Lakh -₹72 Lakh -₹65.6 Lakh -₹15.1 Lakh -₹2.02 Cr ₹6.5 Lakh
Total Comprehensive Income -₹6.41 Cr ₹2.59 Cr ₹149.07 Cr ₹99.49 Cr ₹28.88 Cr ₹1.36 Cr ₹27.99 Cr ₹16.32 Cr ₹38.85 Cr ₹31.5 Cr ₹115.79 Cr ₹110.81 Cr
EBITDA (computed) ₹48.75 Cr ₹102.42 Cr ₹320.47 Cr ₹239 Cr ₹137.72 Cr ₹107.36 Cr ₹148.44 Cr ₹128.54 Cr ₹99.78 Cr ₹77.87 Cr ₹151.47 Cr ₹159.53 Cr
Basic EPS ₹-0.63 ₹0.23 ₹10.98 ₹7.34 ₹2.24 ₹0.13 ₹2.06 ₹1.25 ₹2.90 ₹2.33 ₹8.66 ₹8.14
Diluted EPS ₹-0.63 ₹0.23 ₹10.96 ₹7.33 ₹2.23 ₹0.13 ₹2.06 ₹1.25 ₹2.90 ₹2.33 ₹8.65 ₹8.13
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Eris Lifesciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Eris Lifesciences Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 53.92%, foreign institutional investors hold 6.39%, domestic institutional investors hold 20.35%, retail and other public shareholders hold 19.33% of Eris Lifesciences Limited. The company had 51,656 shareholders on record.

Promoters: 53.92%DII (Domestic Institutional): 20.35%FII (Foreign Institutional): 6.39%Retail & Others: 19.33%
Mar 2026
QUARTER
53.92% Promoters
20.35% DII (Domestic Institutional)
6.39% FII (Foreign Institutional)
19.33% Retail & Others
Promoter holding - history
Now 53.92% · Mar 2026High 56.23% · Jun 2019Low 52.29% · Sep 2022
51%52.8%54.5%56.3%58%Jun 2017Jun 2019Jun 2021Jun 2023Jun 2025Jun 2017: 55.93%Sep 2017: 55.93%Dec 2017: 55.93%Mar 2018: 55.93%Jun 2018: 55.93%Sep 2018: 55.92%Dec 2018: 56.04%Mar 2019: 56.10%Jun 2019: 56.23%Sep 2019: 56.23%Dec 2019: 56.23%Mar 2020: 55.55%Jun 2020: 55.55%Sep 2020: 54.08%Dec 2020: 54.23%Mar 2021: 54.13%Jun 2021: 52.69%Sep 2021: 52.68%Dec 2021: 52.66%Mar 2022: 52.66%Jun 2022: 52.30%Sep 2022: 52.29%Dec 2022: 52.70%Mar 2023: 52.86%Jun 2023: 52.86%Sep 2023: 54.91%Dec 2023: 54.90%Mar 2024: 54.90%Jun 2024: 54.88%Sep 2024: 54.87%Dec 2024: 54.86%Mar 2025: 54.85%Jun 2025: 54.83%Sep 2025: 54.85%Dec 2025: 54.85%Mar 2026: 53.92%56.23%52.29%53.92%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters53.92%54.85%54.85%54.83%54.85%54.86%
Public46.08%45.15%45.15%45.17%45.15%45.14%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
Promoters53.92%54.85%54.90%52.86%52.66%54.13%55.55%56.10%55.93%
Public46.08%45.15%45.10%47.14%47.34%45.87%44.45%43.90%44.07%
Promoter change (YoY, %pts)-0.93-0.05+2.04+0.20-1.47-1.42-0.55+0.17-

Board & Governance of Eris Lifesciences Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Eris Lifesciences Limited has 8 directors - 4 independent and 4 executive. The board is chaired by AMIT INDUBHUSHAN BAKSHI.

DirectorPositionOn board sinceListed boards
AMIT INDUBHUSHAN BAKSHI Executive Director · CEO-MD · Chairperson 2007-01-27 1
KAUSHAL KAMLESH SHAH Executive Director 2020-08-04 1
KRISHNAKUMAR VAIDYANATHAN Executive Director 2020-12-20 1
INDERJEET SINGH NEGI Executive Director 2007-01-27 1
KALPANA VASANTRAI UNADKAT Non-Executive - Independent Director 2021-01-05 3
SUJESH VASUDEVAN Non-Executive - Independent Director 2022-07-25 2
PRASHANT GUPTA Non-Executive - Independent Director 2018-04-30 1
VINEET VARMA Non-Executive - Independent Director 2026-03-14 1
Board Committees
CommitteeMembers
Audit Committee KALPANA VASANTRAI UNADKAT (Chairperson), SUJESH VASUDEVAN, PRASHANT GUPTA, VINEET VARMA
Nomination and remuneration committee SUJESH VASUDEVAN (Chairperson), PRASHANT GUPTA, KALPANA VASANTRAI UNADKAT, VINEET VARMA
Stakeholders Relationship Committee KALPANA VASANTRAI UNADKAT, SUJESH VASUDEVAN (Chairperson), INDERJEET SINGH NEGI
Risk Management Committee KRISHNAKUMAR VAIDYANATHAN (Chairperson), KALPANA VASANTRAI UNADKAT, SACHIN SHAH
Corporate Social Responsibility Committee INDERJEET SINGH NEGI (Chairperson), KAUSHAL KAMLESH SHAH, SUJESH VASUDEVAN, VINEET VARMA

Group Structure of Eris Lifesciences Limited

Eris Lifesciences Limited has 6 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Eris Lifesciences Limited's business expansion strategy and organizational complexity.

6
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Eris Healthcare Private Limited U24211GJ2013PTC113419 -
Eris Therapeutics Limited U24230GJ2021PLC123519 -
Aprica Healthcare Limited U24232GJ2011PLC112374 -
Eris Pharmaceuticals Private Limited U33100UP2020PTC128964 -
Eris M. J. Biopharm Private Limited U51397GJ2002PTC112851 -
Eris Oaknet Healthcare Private Limited U74999MH2011PTC296817 -

Showing major subsidiaries. Total: 6.

Charges & Borrowings of Eris Lifesciences Limited

Open charges
₹1,524.82 Cr
Satisfied charges
₹1,252.5 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹662.00 Cr
Citi Bank N.A.₹525.82 Cr
Axis Bank Limited₹337.00 Cr
Latest charge details
DateLenderAmountStatus
04 Apr 2025 Hdfc Bank Limited ₹150 Cr Open
27 Dec 2023 Hdfc Bank Limited ₹212 Cr Open
21 Dec 2023 Citi Bank N.A. ₹280 Cr Open
21 Aug 2023 Citi Bank N.A. ₹120.82 Cr Open
26 Jul 2023 Axis Bank Limited ₹337 Cr Open

Total charge records: 12 View all charges

Employees and EPFO Compliance at Eris Lifesciences Limited

Eris Lifesciences Limited has a workforce of 3,131 employees as of Mar 06, 2025.

Employee count
3,131
Active EPFO establishments
2
Employee growth
-5.26%
Premium access

Employee and EPFO history for Eris Lifesciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Eris Lifesciences Limited

Premium access

GST registrations and filing compliance for Eris Lifesciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Eris Lifesciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Eris Lifesciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Eris Lifesciences Limited

Premium access

MSME payment history for Eris Lifesciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Eris Lifesciences Limited

Premium access

Corporate group structure for Eris Lifesciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Eris Lifesciences Limited

Premium access

MCA filings and documents for Eris Lifesciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Eris Lifesciences Limited

Directors
14 Mar 2026
Vineet Varma was appointed as a Director on 14 Mar 2026 & has been associated with this company since 6 months 7 days.
Activity
25 Jul 2025
Eris Lifesciences Limited last Annual general meeting of members was held on 25 Jul 2025 as per latest MCA records.
Charges
04 Apr 2025
A charge with Hdfc Bank Limited amounted to Rs. 150.00 Cr with Charge ID 101091534 was registered on 04 Apr 2025.
Activity
31 Mar 2025
Eris Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Charges
21 Feb 2025
A charge registered on 13 Feb 2024 via Charge ID 100890095 with Others was fully satisfied on 21 Feb 2025.
Charges
13 Feb 2024
A charge with Others amounted to Rs. 437.50 Cr with Charge ID 100890095 was registered on 13 Feb 2024.

Recent News on Eris Lifesciences Limited

Frequently Asked Questions about Eris Lifesciences Limited

Eris Lifesciences Limited is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 25 January 2007 (19+ years old) and is registered under CIN L24232GJ2007PLC049867. Listed on BSE: 540596 and NSE: ERIS. The company has 3,131 employees.

Eris Lifesciences Limited reported revenue of ₹3,129.42 Cr for FY 2026 (up 8.15% YoY) based on consolidated NSE filings.

The current directors of Eris Lifesciences Limited are:

The primary industry of Eris Lifesciences Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Eris Lifesciences Limited is listed on both BSE (code: 540596) and NSE (symbol: ERIS).

Eris Lifesciences Limited can be reached at the registered office: Shivarth Ambit Plot No 1422 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054, or through the website eris.co.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available